Several market players in diabetic neuropathy market are increasingly focusing on the development of disease-modifying drugs for the treatment of diabetic neuropathy. The US FDA has approved tablets as a once-daily therapy for managing the neuropathic pain associated with diabetic peripheral neuropathy. Moreover, several companies are also encouraging the development of investigational injection therapies for treating painful diabetic neuropathy. With the approval of new drugs and the presence of a strong drug pipeline, the diabetic neuropathy drugs market will grow significantly during the forecast period. Furthermore, this industry research report also presents a competitive analysis of the market by the mechanism of action (calcium channel alpha-2-delta ligand, SNRIs and TCAs, and others) and geography (Asia, Europe, North America, and ROW).
Competitive vendor landscape
The global diabetic neuropathy drugs market is highly competitive with major vendors such as DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, and Pfizer Inc., competing based on price, quality, and product/service offerings.
“Vendors in the diabetic neuropathy market are also focusing on developing novel biologics for treating diabetic foot ulcer, peripheral arterial disorders, and diabetic neuropathies. Companies are also focused on launching injectable gene therapy aimed at long-term pain relief. In addition to new drug approvals, the constant development of biologics will further boost the diabetic neuropathy drugs market growth in the forthcoming years,” says a senior analyst at Technavio

Top five diabetic neuropathy drugs market vendors
DAIICHI SANKYO COMPANY, LIMITED
DAIICHI SANKYO COMPANY, LIMITED operates in four segments: Innovative Pharmaceuticals Business, Generic Business, Vaccine Business, and OTC Related Business. Its key offering includes Tarlige, which is used to treat peripheral neuropathic pain.
Eli Lilly and Company
Eli Lilly and Company operates through two segments: human pharmaceutical products and animal health products. Its key offering includes CYMBALTA, which is used to treat neuropathic pain.
Johnson & Johnson Services, Inc.
Johnson & Johnson Services operates through three segments: pharmaceutical, medical devices, and consumer. The company’s key offering includes NUCYNTA, which is an opioid analgesic used to treat diabetic neuropathy pain.
Novartis AG
Novartis AG operates through three segments: innovative medicines, Sandoz, Alcon. The company’s key offering includes Tegretol, which is an anticonvulsant medication used primarily for the treatment of neuropathic pain.
Pfizer Inc.
Pfizer Inc. operates through two segments: Innovative Health and Essential Health. The company’s key offering includes NEURONTIN, which is used to treat neuropathic pain.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report, including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
• Global Adrenocortical Carcinoma Drugs Market 2019-2023 - The market research study identifies Bristol-Myers Squibb Co., Eli Lilly and Co., Laboratoire HRA Pharma SAS, Progenics Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd., as the leading players in the global adrenocortical carcinoma drugs market.
• Global Psoriatic Arthritis Therapeutics Market 2019-2023 - The market research study identifies AbbVie Inc., Celgene Corp., Johnson & Johnson Services Inc., Novartis AG, and Pfizer Inc., as the leading players in the global psoriatic arthritis therapeutics market.

About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at [email protected].
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
technavio.com
[email protected].